Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression

Primary Care Psychiatry

Volumn 5, Issue 2, 1999, Pages 57-63

  Alves, Carlos ^a,b   Cachola, Isabel ^a   Brandao, Jose ^a  

^a Wyeth Lederle Portugal   (Portugal)

^b Wyeth Lederle Portugal   (Portugal)

Author keywords

Fluoxetine; Major depression; Remission; Venlafaxine

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ADULT; AGITATION; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SUICIDE ATTEMPT;

EID: 0032837970     PISSN: 13552570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethylcyclohexanol derivative. Biochem Pharmacol 1986; 35:4493-4497.
2. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiat 1996; 20:57-71.
3. McPartlin GM, Reynolds A, Anderson C, Casoy J. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiat 1998; 4:127-132.
4. Tylee A, Beaumont G, Bowden M, Reynolds A. A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiat 1997; 3:51-58.
5. Mehtonen O-P, Behnke K, Sogaard J, Roponen P and the Venlafaxine 631 Study Group. Randomized, double-blind comparison of venlafaxine and setraline in outpatients with major depression. J Clin Psychiat, in press.
6. Costa e Silva JA. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiat 1998; 59:352-357.
7. Poirier M-F, Boyer P. Double-blind, randomized comparison of venlafaxine and paroxetine for treatment-resistant depression. Br J Psychiat 1999; in press.
8. Rudolph RL, Fabre LF, Feighner JP, Rickels K. Entsuah R, Derivan AT. A randomized, placebo-controlled, dose - response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiat 1998; 59:116-122.
9. Benkert O. Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed patients with inadequate treatment response. Acta Psychiat Scand 1997; 95:288-296.
10. Preskorn SH, Lane RM. Setraline 50 mg: optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10:129-141.
11. Harvey AT, Preskorn SH. Mechanism of action of venlafaxine in normal male volunteers. Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 1995, San Diego, California.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press, 1994.
13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296.
14. Montgomery AS, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiat 1979; 134:382-389.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institutes of Mental Health, 1976.
16. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiat 1995; 59:450-458.
17. Benkert O, Gründer G, Wetzel H, Hackett D. A randomised double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiat Res 1996; 30:441-451.
18. Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin-Prascual R, Basquedano G et al. A randomized, open comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 1998; 20:467-476.
19. Clerc GE, Ruimy P, Verdeau-Paillès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. Int Clin Psychopharmacol 1994; 9:139-143.
20. Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose - response study. J Clin Psychopharmacol 1998; 18:19-25.
21. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995; 10(Suppl 2):15-20.
22. Rudolph RL. Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996; 16(Suppl 2):54S-61S.
23. Judd LL, Rapaport MH. Effect of pharmacotherapy on suicidal ideation and behavior. Depression 1995; 2:169-172.
24. Henry JA. Suicide risk and antidepressant treatment. J Psychopharmacol 1996; 10(Suppl 1):39-40.
25. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiat 1994; 55:394-400.